Prediction of preterm pre-eclampsia and preterm small-for-gestational-age at 24–28 weeks of gestation using ultrasound and biochemical markers in high-risk pregnancies treated with aspirin: A secondary analysis of the StopPRE trial使用超声和生物化学标志物预测接受阿司匹林治疗的高危妊娠在24~28周时的早产子痫前期和早产胎儿宫内生长受限:StopPRE试验的二次分析INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICSIF2.42026-09-300PRE
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trialACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICAIF3.12024-08-222OAAI
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factorACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICAIF3.12023-10-092OA
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial CommentOBSTETRICAL & GYNECOLOGICAL SURVEYIF3.62023-08-010PRE
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia A Randomized Clinical TrialJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552023-02-2124OA
Maternal and Perinatal Outcomes Associated With Extremely High Values for the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor) RatioJOURNAL OF THE AMERICAN HEART ASSOCIATIONIF5.32020-04-0918OAAI